We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01559454
Recruitment Status : Completed
First Posted : March 21, 2012
Results First Posted : February 20, 2017
Last Update Posted : February 20, 2017
Sponsor:
Information provided by (Responsible Party):
State University of New York at Buffalo

Brief Summary:
Chronic pain patients are treated with prescription opioids and many exhibit opioid addiction. Currently, there are no evidence-based guidelines to better manage patients with chronic pain and coexistent opioid addiction. This study compares 6-months buprenorphine and methadone treatment in these patients. The investigators hypothesize that both buprenorphine and methadone treatment will reduce pain and addiction behaviors and increase functioning in these patients.

Condition or disease Intervention/treatment Phase
Low Back Pain Drug: Methadone Drug: Buprenorphine/naloxone Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients
Study Start Date : February 2012
Primary Completion Date : May 2014
Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Methadone
10-60 mg/day divided by 2-4 times a day
Drug: Methadone
10-60 mg/day divided by 2-4 times a day for 6 months
Other Name: Dolophine
Experimental: Buprenorphine/naloxone
4-16 mg/day divided by 2-4 times a day
Drug: Buprenorphine/naloxone
4-16 mg/day divided by 2-4 times a day for 6 months
Other Name: Suboxone



Primary Outcome Measures :
  1. Analgesia [ Time Frame: 6 months ]
    Pain severity will be measured using the Visual Analogue Scale (VAS) which has a range of 0-100 with 0 being no pain and 100 being worse possible pain.


Secondary Outcome Measures :
  1. Illicit Drug Use [ Time Frame: 6 months ]
    Illicit opioid use will be measured by self-report and confirmed with urine toxicology.

  2. Cravings [ Time Frame: at 6 months ]
    Cravings will be assessed using the Visual Analogue Scale (VAS) with 0 being no cravings and 100 being worse possible cravings

  3. Functioning [ Time Frame: at 6 months ]
    Functioning will be assessed using the Visual Analogue Scale (VAS) with 0 being "no limits" and 100 being "bedridden."

  4. Depression [ Time Frame: at 6 months ]
    Depression will be assessed using the Beck Depression Inventory, a 63 point scale with 0 being "none" and 63 being "severe."

  5. Treatment Retention [ Time Frame: 6 months ]
    Number of participants that completed the study protocol



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. have a well-documented chronic pain disorder due to past back surgery,
  2. have a chronic back pain syndrome,
  3. have evidence of opioid addiction,
  4. prior attempt at abstinence-oriented treatment documented by the referring physician,
  5. be able to understand spoken and written English,
  6. reside in Erie or Niagara counties,
  7. have health insurance or other ability to pay for treatment with the approval from patient's primary physician;
  8. have no prior history of methadone or BUP/NLX maintenance treatment since the last surgery,
  9. not be a member of a vulnerable population, including prisoners

Exclusion Criteria:

  1. homeless, or any patient without a "locator" (no means to participate in the follow-up data collection interviews by phone),
  2. inability to give consent,
  3. those with major co-occurring psychiatric disorders,
  4. EKG showing prolonged QT and/or previous cardiac issues,
  5. are taking a medication that is contraindicated with methadone,
  6. medically unstable,
  7. urine positive for cocaine at initial visit,
  8. pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01559454


Locations
United States, New York
UB/MD Family Medicine, Inc.
Amherst, New York, United States, 14228
Sponsors and Collaborators
State University of New York at Buffalo
Investigators
Study Director: Rachel A Rizzo, MPH University at Buffalo

Publications:
Responsible Party: State University of New York at Buffalo
ClinicalTrials.gov Identifier: NCT01559454     History of Changes
Other Study ID Numbers: FMD0600908A
First Posted: March 21, 2012    Key Record Dates
Results First Posted: February 20, 2017
Last Update Posted: February 20, 2017
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: We are preparing a de-identified data set that could be shared.

Keywords provided by State University of New York at Buffalo:
chronic pain
opioid dependence
methadone
buprenorphine
substance use disorder

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Analgesics, Opioid
Buprenorphine
Methadone
Buprenorphine, Naloxone Drug Combination
Naloxone
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Antitussive Agents
Respiratory System Agents